Damora Therapeutics (DMRA)

• Market cap: $1.34B
• 1 day: 1.26%
• 5 days: 1.31%
• 1 month: -12.89%
• 3 months: 2.55%
• 6 months: -16.58%
• Year to date: -0.6%
• 1 year: 551.35%
• 5 years: -82.92%
• 10 years: -94.22%
• Sector: Healthcare
• Industry: Biotechnology

About: Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Employees: 7